Search results for "Chronic hepatitis C infection"

showing 2 items of 2 documents

Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients

2012

Background: Hepatitis C virus infection is characterised by enhanced oxidative stress, which can be measured quantitatively by plasma oxysterol concentration. These molecules may affect lipid metabolism through the activation of Liver X Receptors. Hepatitis C virus exploits host lipid metabolism to facilitate its replication and diffusion. In our study we aimed to evaluate and highlight the potential pathogenetic role of oxysterols, 7-ketocholesterol and 7-β-hydroxycholesterol, in hepatitis C virus-related lipid dysmetabolism. Methods: The study was performed in 42 patients with chronic hepatitis C (93% genotype 1b) and 38 non-alcoholic fatty liver disease patients. Plasma oxysterols 7-keto…

AdultMalemedicine.medical_specialtyOxysterolHepatitis C virusHepacivirusIsotope dilutionmedicine.disease_causechronic hepatitis c infection; lipid metabolism; non-alcoholic fatty liver disease; oxidative stressNon-alcoholic Fatty Liver DiseaseInternal medicinemedicinepolycyclic compoundsoxysterol hcv nafldHumansoxysterols sterols cholesterol mass spectrometry metabolomicsLiver X receptorKetocholesterolsHepatologybusiness.industryFatty liverGastroenterologyLipid metabolismHepatitis CCholesterol LDLMiddle Agedmedicine.diseaseHepatitis CChronic hepatitis C infectionHydroxycholesterolsFatty LiverOxidative StressEndocrinologyLipid metabolismBiochemistryMultivariate AnalysisLinear Modelslipids (amino acids peptides and proteins)FemalebusinessOxidative stress
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct